|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
DE3169595D1
(en)
|
1980-11-10 |
1985-05-02 |
Gersonde Klaus |
Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
DE3374837D1
(en)
|
1982-02-17 |
1988-01-21 |
Ciba Geigy Ag |
Lipids in the aqueous phase
|
|
DE3218121A1
(de)
|
1982-05-14 |
1983-11-17 |
Leskovar, Peter, Dr.-Ing., 8000 München |
Arzneimittel zur tumorbehandlung
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
EP0143949B1
(en)
|
1983-11-01 |
1988-10-12 |
TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION |
Pharmaceutical composition containing urokinase
|
|
JPS62126123A
(ja)
*
|
1985-11-28 |
1987-06-08 |
Shigeki Suzuki |
バルプロ酸の経皮吸収方法
|
|
JPH06510290A
(ja)
*
|
1991-08-27 |
1994-11-17 |
シグナス，インコーポレイテッド |
プラゾシンを投与するための経皮処方物
|
|
EP0819016A1
(de)
*
|
1995-04-07 |
1998-01-21 |
Novartis AG |
Iontophoretisches transdermales system zum verabreichen von mindestens zwei substanzen
|
|
US5736154A
(en)
|
1996-03-11 |
1998-04-07 |
Fuisz Technologies Ltd. |
Transdermal delivery system
|
|
FR2749514B1
(fr)
*
|
1996-06-11 |
1998-08-07 |
Hoechst Marion Roussel |
Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
|
|
US6479074B2
(en)
*
|
1996-10-24 |
2002-11-12 |
Pharmaceutical Applications Associates Llc |
Methods and transdermal compositions for pain relief
|
|
AU5495798A
(en)
|
1997-01-16 |
1998-08-07 |
Sekisui Chemical Co., Ltd. |
External preparations for percutaneous absorption
|
|
AU4841599A
(en)
|
1998-06-29 |
2000-01-17 |
Pharmaceuticals Applications Asociates, Llc |
Methods and transdermal compositions for pain relief
|
|
AU780454B2
(en)
|
1999-06-03 |
2005-03-24 |
Jessie L.S. Au |
Methods and compositions for modulating cell proliferation and cell death
|
|
IL138686A0
(en)
|
1999-10-01 |
2001-10-31 |
Pfizer Prod Inc |
α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
|
|
JP2004504585A
(ja)
*
|
2000-07-14 |
2004-02-12 |
トランスフォーム ファーマシューティカルズ，インコーポレーティッド． |
化合物の組織バリア輸送を最適にするためのシステムおよび方法
|
|
US6682757B1
(en)
*
|
2000-11-16 |
2004-01-27 |
Euro-Celtique, S.A. |
Titratable dosage transdermal delivery system
|
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
|
EP1293205A1
(en)
|
2001-09-18 |
2003-03-19 |
G2M Cancer Drugs AG |
Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
|
|
DE60238276D1
(de)
|
2001-12-13 |
2010-12-23 |
Vital Health Sciences Pty Ltd |
Transdermaler transport von verbindungen
|
|
US6841565B1
(en)
|
2002-03-29 |
2005-01-11 |
The Ohio State University |
Treatment of patients with chronic lymphocytic leukemia
|
|
CN1795193B
(zh)
|
2003-05-20 |
2010-08-18 |
诺瓦提斯公司 |
用作过氧化物酶体增殖物激活受体的配体的n-酰基含氮杂环化合物
|
|
JP2009513523A
(ja)
|
2003-07-08 |
2009-04-02 |
ノバルティス アクチエンゲゼルシャフト |
ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物
|
|
US20050059682A1
(en)
|
2003-09-12 |
2005-03-17 |
Supergen, Inc., A Delaware Corporation |
Compositions and methods for treatment of cancer
|
|
US8012944B2
(en)
*
|
2003-10-30 |
2011-09-06 |
Pharmascience Inc. |
Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
|
|
US7582782B2
(en)
|
2003-11-26 |
2009-09-01 |
Novartis Ag |
Organic compounds
|
|
WO2005065668A2
(en)
|
2003-12-29 |
2005-07-21 |
Qlt Usa, Inc. |
Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
|
|
US20050255150A1
(en)
|
2004-04-26 |
2005-11-17 |
Cassel Douglas R |
Wound treatment patch for alleviating pain
|
|
KR100602434B1
(ko)
|
2004-09-10 |
2006-07-19 |
최상식 |
복수 개의 단위 구획을 포함하는 약물의 경피 투여용 패치
|
|
AU2006283677A1
(en)
|
2005-08-19 |
2007-03-01 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Topical formulations of histone deacetylase inhibitors and methods of using the same
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
WO2007041584A2
(en)
*
|
2005-10-03 |
2007-04-12 |
Combinatorx, Incorporated |
Implantable sensors, implantable pumps, and anti-scarring drug combinations
|
|
AU2005339587B2
(en)
|
2005-11-16 |
2011-11-03 |
Universidad Nacional Autonoma De Mexico |
Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer
|
|
EP3000480A1
(en)
|
2005-12-01 |
2016-03-30 |
ProNAi Therapeutics, Inc. |
Cancer therapies and pharmaceutical compositions used therein
|
|
WO2007067695A2
(en)
|
2005-12-07 |
2007-06-14 |
University Of Utah Research Foundation |
Dna methylation as a target for diagnosis and treatment of chronic lymphocytic leukemia (cll)
|
|
EP2522352B1
(en)
|
2006-03-02 |
2017-01-11 |
Agency for Science, Technology and Research |
Methods for stem cells modulation
|
|
US8585753B2
(en)
*
|
2006-03-04 |
2013-11-19 |
John James Scanlon |
Fibrillated biodegradable prosthesis
|
|
WO2007109178A2
(en)
|
2006-03-16 |
2007-09-27 |
Pharmacyclics, Inc. |
Indole derivatives as inhibitors of histone deacetylase
|
|
WO2007114697A1
(en)
|
2006-03-31 |
2007-10-11 |
Erasmus University Medical Center Rotterdam |
Novel composition for tumor growth control
|
|
EP2018161B1
(en)
*
|
2006-05-05 |
2011-07-13 |
Coloplast A/S |
A pressure sensitive adhesive composition comprising cross-linked polyalkylene oxide and water absorbent hydrophilic agents
|
|
WO2008082646A2
(en)
|
2006-12-28 |
2008-07-10 |
The Johns Hopkins University |
Histone deacetylase inhibitors, combination therapies and methods of use
|
|
KR20090110913A
(ko)
|
2007-02-15 |
2009-10-23 |
노파르티스 아게 |
Ｌｂｈ589와 암을 치료하기 위한 다른 치료제와의 조합물
|
|
WO2008116163A1
(en)
|
2007-03-22 |
2008-09-25 |
Oregon Health & Science University |
Therapeutic drug combinations for treatment of b-cell malignancies
|
|
WO2008127735A1
(en)
|
2007-04-13 |
2008-10-23 |
Stemline Therapeutics, Inc. |
Il3ralpha antibody conjugates and uses thereof
|
|
US20090025274A1
(en)
|
2007-07-23 |
2009-01-29 |
Tim Lail |
Animal trap
|
|
WO2009055343A2
(en)
|
2007-10-22 |
2009-04-30 |
Schering Corporation |
Fully human anti-vegf antibodies and methods of using
|
|
WO2009067543A2
(en)
|
2007-11-19 |
2009-05-28 |
The Regents Of The University Of Colorado |
Treatment of histone deacetylase mediated disorders
|
|
US20090131367A1
(en)
*
|
2007-11-19 |
2009-05-21 |
The Regents Of The University Of Colorado |
Combinations of HDAC Inhibitors and Proteasome Inhibitors
|
|
EP3692983B1
(en)
|
2008-05-15 |
2021-08-11 |
Celgene Corporation |
Oral formulations of cytidine analogs and methods of use thereof
|
|
WO2009155477A1
(en)
|
2008-06-19 |
2009-12-23 |
The Trustees Of The University Of Pennsylvania |
Inducible regulatory t-cell generation for hematopoietic transplants
|
|
WO2010020787A1
(en)
|
2008-08-22 |
2010-02-25 |
Oncomethylome Sciences Sa |
Diagnosis and treatment of tumours
|
|
ES2628219T3
(es)
*
|
2009-05-19 |
2017-08-02 |
Vivia Biotech S.L. |
Métodos para proporcionar ensayos de medicina personalizada ex vivo para neoplasias hematológicas
|
|
US8491927B2
(en)
*
|
2009-12-02 |
2013-07-23 |
Nimble Epitech, Llc |
Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
|
|
JP5548470B2
(ja)
*
|
2010-02-16 |
2014-07-16 |
日本碍子株式会社 |
ハニカム触媒体
|
|
WO2011113013A2
(en)
*
|
2010-03-11 |
2011-09-15 |
Hemaquest Pharmaceuticals, Inc. |
Methods and compositions for treating viral or virally-induced conditions
|
|
EP2382993A1
(en)
*
|
2010-04-19 |
2011-11-02 |
KTB Tumorforschungsgesellschaft mbH |
Combination of drugs with protein-binding prodrugs
|
|
US20130244963A1
(en)
*
|
2010-09-30 |
2013-09-19 |
Portola Pharmaceuticals, Inc. |
Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
|
|
TR201903859T4
(tr)
*
|
2010-11-12 |
2019-04-22 |
Pharma Mar Sa |
Bir antitümör antibiyotik ile kombinasyon terapisi.
|
|
US20130004481A1
(en)
*
|
2011-01-12 |
2013-01-03 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
|
CN103596951A
(zh)
*
|
2011-04-08 |
2014-02-19 |
阿弗拉克西斯控股股份有限公司 |
用于治疗神经系统障碍和癌症的8-乙基-6-(芳基)吡啶并[2,3-d]嘧啶-7(8h)-酮
|
|
WO2012142480A1
(en)
*
|
2011-04-14 |
2012-10-18 |
Beth Israel Deaconess Medical Center, Inc. |
Chimeric rna oligonucleotides and uses thereof
|
|
US20140170148A1
(en)
*
|
2011-04-20 |
2014-06-19 |
Genmab A/S |
Bispecific antibodies against her2
|
|
JP2014519813A
(ja)
*
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
|
|
AU2012275275A1
(en)
*
|
2011-06-28 |
2014-01-23 |
Pharmacyclics Llc |
Methods and compositions for inhibition of bone resorption
|
|
BR112014010417A2
(pt)
*
|
2011-11-01 |
2014-11-18 |
Celgene Corp |
Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina
|
|
US20130158043A1
(en)
*
|
2011-12-09 |
2013-06-20 |
Afraxis, Inc. |
Pak inhibitors for the treatment of cancer
|
|
US8921367B2
(en)
*
|
2012-05-31 |
2014-12-30 |
Amgen Inc. |
Use of AMG 900 for the treatment of cancer
|
|
SG11201408067YA
(en)
*
|
2012-06-04 |
2015-01-29 |
Pharmacyclics Inc |
Crystalline forms of a bruton's tyrosine kinase inhibitor
|
|
WO2014009318A1
(en)
*
|
2012-07-11 |
2014-01-16 |
Boehringer Ingelheim International Gmbh |
3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer
|
|
WO2014009319A1
(en)
*
|
2012-07-11 |
2014-01-16 |
Boehringer Ingelheim International Gmbh |
Indolinone derivatives anticancer compounds
|
|
JP6347782B2
(ja)
*
|
2012-08-09 |
2018-06-27 |
セルジーン コーポレイション |
３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンを使用する癌の治療方法
|
|
NZ628030A
(en)
*
|
2012-08-09 |
2016-12-23 |
Celgene Corp |
Salts and solid forms of (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
|
|
US9682143B2
(en)
*
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
AU2013302696B9
(en)
*
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
US20140120083A1
(en)
*
|
2012-11-01 |
2014-05-01 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
|
KR20230078823A
(ko)
*
|
2012-12-13 |
2023-06-02 |
이뮤노메딕스, 인코오포레이티드 |
개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약
|
